{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-005319","form_type":"8-K","ticker":"GH","cik":"0001576280","company_name":"Guardant Health, Inc.","filed_at":"2025-01-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.049016+00:00","generated_at":"2026-05-28T03:20:10.143370+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Guardant Health reports preliminary Q4 revenue ~$200M (+29% YoY); FY24 revenue $737M (+31%)","bullets":["Total revenue Q4 ~$200M (+29% YoY); full year ~$737M (+31% YoY).","Oncology clinical tests (ex-Shield) Q4 57,300 (+24%); full year 206,700 (+20%).","Biopharma tests Q4 11,050 (+16%); full year 40,500 (+35%).","Shield screening tests Q4 6,400 with ~$4M revenue in first full commercial quarter.","Free cash flow -$84M in Q4, -$275M full year; cash & securities $944M at Dec 31, 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-005319","json":"https://secwatch.observer/filing/0001193125-25-005319.json","markdown":"https://secwatch.observer/filing/0001193125-25-005319.md","text":"https://secwatch.observer/filing/0001193125-25-005319.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1576280/000119312525005319/0001193125-25-005319-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1576280/000119312525005319/d890861d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T03:20:10.143370+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}